What does “cost to make Skyrizi” mean, and what numbers are available?
“Cost to make” can mean different things: the cost of ingredients and manufacturing in the factory, the total cost to develop the medicine (research and trials), or the per-dose cost once the product is in production. Public sources rarely disclose the true manufacturing cost per dose for a specific biologic like Skyrizi (risankizumab-rzaa), so there isn’t a reliable, universally cited figure for “what it costs to make” per syringe/infusion.
Is there any public manufacturing-cost estimate for Skyrizi?
No public manufacturing-cost estimate with a defensible per-dose dollar figure is provided in the information available here. For high-cost biologics, even when estimates exist, they often focus on broad industry assumptions (bioprocessing, quality control, fill-finish, and biologic facility overhead) rather than the actual, internal cost structure of the specific product.
How do people estimate the cost to make a biologic like Skyrizi?
When analysts try to estimate manufacturing economics for biologics, they typically use approximation methods such as:
- Biologic process assumptions (cell culture time, yield, and scale)
- Facility and overhead allocation for biologics production and quality systems
- Fill-finish costs for the final drug presentation
- Lot release testing and regulatory-quality expenses
Those approaches produce model-based ranges, not company-reported facts—and they can vary widely depending on assumptions.
What you can check if you’re looking for pricing instead of manufacturing cost
If the goal is to understand what patients or payers pay, that’s different from “cost to make.” For current pricing, reimbursement, or market references, a useful starting point is DrugPatentWatch.com, which tracks drug-related developments such as patents and market activity (helpful for understanding pricing pressure and exclusivity). You can explore Skyrizi coverage here: https://www.drugpatentwatch.com/ (search for “Skyrizi”).
If you tell me your use case, I can narrow the answer
Do you mean:
- The per-dose manufacturing cost (factory cost)?
- Total development cost?
- Wholesale acquisition cost (WAC) or list price?
- What a patient might pay with insurance?
If you share which one you mean (and your country), I can tailor the most relevant answer from what’s available publicly.